Inventor · disambiguated record
Richard F. Clark
Also filed as: CLARK RICHARD · CLARK RICHARD F
30 granted patents·12 pending applications·647 citations·filing 1997–2017
97Inventor score
Top patents by PatentIndex Score
42 records- 0195US5866549A6-O-substituted ketolides having antibacterial activityABBOTT LAB·Filed 1997·Granted Feb 2, 1999·176 cites·14 claims
- 0292US7119205B2Thienopyridones as AMPK activators for the treatment of diabetes and obesityABBOTT LAB·Filed 2004·Granted Oct 10, 2006·47 cites·14 claims
- 0390US8975398B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Mar 10, 2015·13 cites·13 claims
- 0487US6124269A2-Halo-6-O-substituted ketolide derivativesABBOTT LAB·Filed 1998·Granted Sep 26, 2000·97 cites·14 claims
- 0583US9187472B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Nov 17, 2015·5 cites·1 claims
- 0682US6075133A6-O-substituted antibacterial erythromycin ketolides and methods of makingABBOTT LAB·Filed 1998·Granted Jun 13, 2000·43 cites·12 claims
- 0782US6054435A6-O-substituted macrolides having antibacterial activityABBOTT LAB·Filed 1999·Granted Apr 25, 2000·74 cites·14 claims
- 0881US7928243B2Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndromeABBOTT LAB·Filed 2007·Granted Apr 19, 2011·4 cites·11 claims
- 0980US6028181A6-0-Substituted antibacterial erythromycin ketolides and methods of makingABBOTT LAB·Filed 1998·Granted Feb 22, 2000·36 cites·9 claims
- 1079US8748627B2Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndromeGU YU GUI·Filed 2007·Granted Jun 10, 2014·6 cites·29 claims
- 1176US9193723B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Nov 24, 2015·2 cites·18 claims
- 1276US5780605A6,9-bridged erythromycin derivativesABBOTT LAB·Filed 1997·Granted Jul 14, 1998·37 cites·9 claims
- 1375US8354422B2Pyrimidine inhibitors of kinase activityABBOTT LAB·Filed 2010·Granted Jan 15, 2013·2 cites·18 claims
- 1475US6355620B1C-2 modified erythromycin derivativesABBOTT LAB·Filed 1999·Granted Mar 12, 2002·38 cites·13 claims
- 1574US9296723B2NAMPT inhibitorsABBVIE INC·Filed 2013·Granted Mar 29, 2016·1 cites·8 claims
- 1673US9302989B2NAMPT and rock inhibitorsCURTIN MICHAEL L·Filed 2011·Granted Apr 5, 2016·4 cites·20 claims
- 1770US6075011A6-O-substituted erythromycin compounds and method for making sameABBOTT LAB·Filed 1997·Granted Jun 13, 2000·30 cites·29 claims
- 1869US6933283B211-deoxy azalide antibacterialsABBOTT LAB·Filed 2003·Granted Aug 23, 2005·3 cites·17 claims
- 1968USRE39591E6-O-substituted ketolides having antibacterial activityABBOTT LAB·Filed 2004·Granted Apr 24, 2007·2 cites·19 claims
- 2063US6147197A6-O-substituted erythromycin ketolides having antibacterial activityFiled 1998·Granted Nov 14, 2000·14 cites·4 claims
- 2161US9051315B2Imidazopyridines as a novel scaffold for multi-targeted kinase inhibitionBA-MAUNG NWE Y·Filed 2010·Granted Jun 9, 2015·1 cites·4 claims
- 2260US6831068B2Macrolide antibacterial compoundsABBOTT LAB·Filed 2003·Granted Dec 14, 2004·1 cites·6 claims
- 2355US9758511B2NAMPT inhibitorsABBVIE INC·Filed 2016·Granted Sep 12, 2017·0 cites·7 claims
- 2454US8163769B2Antibacterial compoundsANDERSON DAVID·Filed 2003·Granted Apr 24, 2012·1 cites·19 claims
- 2554US2006287356A1Thienopyridones as AMPK activators for the treatment of diabetes and obesityIYENGAR RAJESH R·Filed 2006·Application pending·0 cites
- 2653US5780604A11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolidesABBOTT LAB·Filed 1997·Granted Jul 14, 1998·10 cites·13 claims
- 2752US2016184281A1Nampt inhibitorsABBVIE INC·Filed 2015·Application pending·0 cites
- 2852US2017065575A1Nampt inhibitorsABBVIE INC·Filed 2016·Application pending·0 cites
- 2952US2004033970A1Antibacterial compounds with improved pharmacokinetic profilesFiled 2003·Application pending·0 cites
- 3052US2017135994A9Nampt inhibitorsABBVIE INC·Filed 2015·Application pending·0 cites
- 3148US8067409B2Protein kinase inhibitorsBA-MAUNG NWE Y·Filed 2008·Granted Nov 29, 2011·0 cites·12 claims
- 3247US2015141398A1Nampt inhibitorsABBVIE INC·Filed 2015·Application pending·0 cites
- 3344US2006178400A1Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndromeBEUTEL BRUCE A·Filed 2005·Application pending·0 cites
- 3444US2003207820A1Antibacterial compounds with improved pharmacokinetic profilesFiled 2002·Application pending·0 cites
- 3543US9957274B2Indane inhibitors of EED and methods of their useABBVIE INC·Filed 2017·Granted May 1, 2018·0 cites·9 claims
- 3642US2002193320A1C-2 modified erythromycin derivativesFiled 2000·Application pending·0 cites
- 3741US2005267054A1Antibacterial compounds with improved pharmacokinetic profilesCLARK RICHARD F·Filed 2005·Application pending·0 cites
- 3840US9796708B2Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitorsABBVIE INC·Filed 2014·Granted Oct 24, 2017·0 cites·11 claims
- 3939US2003171308A1Macrolide antibacterial compoundsFiled 2002·Application pending·0 cites
- 4038US8691810B2Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinasesMICHAELIDES MICHAEL R·Filed 2011·Granted Apr 8, 2014·0 cites·17 claims
- 4137US2006166906A16-O-substituted erythromycin derivatives having improved gastrointestinal toleranceMA ZHENKUN·Filed 2001·Application pending·0 cites
- 4235US8536180B2Pyrimidine inhibitors of kinase activityCLARK RICHARD F·Filed 2010·Granted Sep 17, 2013·0 cites·25 claims
Join the waitlist — get patent alerts
Get an alert when Richard F. Clark files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →